Evidence map›Paper›PMID 21454882›Full record

ArticleHaematologica2011

Methylation profiling of mediastinal gray zone lymphoma reveals a distinctive signature with elements shared by classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma.

Franziska C Eberle, Jaime Rodriguez-Canales, Lai Wei, Jeffrey C Hanson, J Keith Killian, Hong-Wei Sun, Lisa G Adams, Stephen M Hewitt, Wyndham H Wilson, Stefania Pittaluga and 4 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in Haematologica, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 143 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. [Gray zone lymphoma: five cases report and literature review].Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi · 2023
    Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 3 countries.

Franziska C EberleLaboratory of Pathology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Jaime Rodriguez-Canales
Lai Wei
Jeffrey C Hanson
J Keith Killian
Hong-Wei Sun
Lisa G Adams
Stephen M Hewitt
Wyndham H Wilson
Stefania Pittaluga
Paul S Meltzer
Louis M Staudt
Michael R Emmert-Buck
Elaine S Jaffe
National Institutes of Health · USCenter for Cancer Research · USCenter for Translational Molecular Medicine · NLNational Cancer Institute · USNational Eye Institute · US

Funding

Molecular diagnosis and outcome prediction in lymphomaZIABC011006 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI STAUDT, LOUIS · 2009 to 2025
$21.0M
Lymphoma Disease Discovery and DefintionZIASC000550 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI JAFFE, ELAINE · 2009 to 2025
$16.9M
Cancer Genomics Technology DevelopmentZIABC011091 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI MELTZER, PAUL S. · 2009 to 2025
$16.9M
Applying Bioinformatics to Research in Immune, Muscle, and Bone DiseasesZIHAR041173 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI GADINA, MASSIMO · 2009 to 2020
$11.0M
Therapeutic Strategies and Molecular Correlates in Aggressive B-cell LymphomasZIASC006741 · NCI · DIVISION OF CLINICAL SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2025
$10.4M
Tissue Array Research ProgramZICBC010923 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI HEWITT, STEPHEN · 2009 to 2014
$4.7M
Targeted treatment of B-cell LymphomaZIABC011354 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2010 to 2025
$4.6M
Phase III Study of R-CHOP v DA-EPOCH-R with microarrayZIABC010728 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2021
$1.4M
Phase III study of BCL-family inhibitors in lymphomaZIABC010716 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI WILSON, WYNDHAM H · 2009 to 2013
$1.1M
Intramural NIH HHS
6 · The paper itself

Abstract

backgroundMediastinal gray zone lymphoma is a newly recognized entity with transitional morphological and immunophenotypic features between the nodular sclerosis subtype of Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. Diagnostic criteria for mediastinal gray zone lymphoma are still challenging, and the optimal therapy is as yet undetermined. Epigenetic changes have been implicated in the loss of the B-cell program in classical Hodgkin's lymphoma, and might provide a basis for the immunophenotypic alterations seen in mediastinal gray zone lymphoma. DESIGN AND

methodsWe performed a large-scale DNA methylation analysis of microdissected tumor cells to investigate the biological underpinnings of mediastinal gray zone lymphoma and its association with the related entities classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma, making comparisons with the presumptively less related diffuse large B-cell lymphoma.

resultsPrincipal component analysis demonstrated that mediastinal gray zone lymphoma has a distinct epigenetic profile intermediate between classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma but remarkably different from that of diffuse large B-cell lymphoma. Analysis of common hypo- and hypermethylated CpG targets in mediastinal gray zone lymphoma, classical Hodgkin's lymphoma, primary mediastinal large B-cell lymphoma and diffuse large B-cell lymphoma was performed and confirmed the findings of the principal component analysis. Based on the epigenetic profiles we were able to establish class prediction models utilizing genes such as HOXA5, MMP9, EPHA7 and DAPK1 which could distinguish between mediastinal gray zone lymphoma, classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma with a final combined prediction of 100%.

conclusionsOur data confirm a close relationship between mediastinal gray zone lymphoma and both classical Hodgkin's lymphoma and primary mediastinal large B-cell lymphoma. However, important differences were observed as well, allowing a clear distinction from both parent entities. Thus, mediastinal gray zone lymphoma cannot be assigned to either classical Hodgkin's lymphoma or primary mediastinal large B-cell lymphoma, validating the decision to create an intermediate category in the World Health Organization classification.

Indexed as

EpigenomicsAdolescentAdultAgedAged, 80 and overCell Line, TumorCluster AnalysisCpG IslandsDNA MethylationFemaleHumansLymphomaMaleMediastinal NeoplasmsMiddle AgedModels, GeneticPolycomb-Group ProteinsRepressor Proteins

Identifiers

PMID21454882
PMCPMC3069233
OpenAlexW1997148851

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.